AGN - Evolus: Much Better Than Expected

Introduction

I recently wrote an article about Revance Therapeutics' (RVNC) long-acting DAXI (DaxiBotulinumToxinA) and how the Phase III data was compelling enough to make me open a long position in RVNC. As an investor, I think it is paramount to always fully assess any competition that poses a threat to your capital. In fact, I only founded RVNC after a lengthy reassessment of my extremely overweight AbbVie (ABBV) position. After my article on RVNC, I received some private messages regarding Evolus' (EOLS) Jeuveau, and whether or not it can capture significant